| Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade |
The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-13 15:01:08 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Reports First Quarter 2025 Financial Results |
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo. |
globenewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders |
WALTHAM, Mass. and BOULDER, Colo. |
globenewswire.com |
2025-04-25 12:08:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting |
Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics |
globenewswire.com |
2025-03-25 18:31:00 |
Czytaj oryginał (ang.) |
| Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? |
Cogent Biosciences (COGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
zacks.com |
2025-03-20 11:35:17 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Participation in the Leerink Healthcare Conference |
WALTHAM, Mass. and BOULDER, Colo. |
globenewswire.com |
2025-03-07 10:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients |
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results |
• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2 nd -line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? |
Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year. |
zacks.com |
2025-02-11 12:40:35 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting |
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025. |
globenewswire.com |
2025-02-10 11:15:00 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks With Notable Insider Buying |
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners. |
seekingalpha.com |
2025-01-22 14:29:06 |
Czytaj oryginał (ang.) |
| Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data |
Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap. |
seekingalpha.com |
2025-01-18 05:27:32 |
Czytaj oryginał (ang.) |
| Why Is Cogent Biosciences Stock Trading Higher On Monday? |
On Sunday, Cogent Biosciences, Inc. COGT revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. |
benzinga.com |
2024-12-09 14:52:46 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients |
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS |
globenewswire.com |
2024-12-09 09:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) |
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached Top-line data from APEX Part 2 on-track for mid-2025 Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass. |
globenewswire.com |
2024-12-08 14:00:00 |
Czytaj oryginał (ang.) |
| Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting |
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news. |
zacks.com |
2024-06-28 14:20:18 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) |
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions |
globenewswire.com |
2024-06-14 11:30:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer |
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST). |
globenewswire.com |
2024-05-23 21:05:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting |
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated lead-in data from the company's ongoing Phase 3 PEAK trial evaluating the selective and potent KIT mutant inhibitor, bezuclastinib, in combination with sunitinib, in patients with Gastrointestinal Stromal Tumors (GIST). The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1. Cogent also announced today a new Phase 2 clinical trial of bezuclastinib plus sunitinib in later line GIST patients, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC) and in collaboration with The Life Raft Group and Dana-Farber Cancer Institute. |
globenewswire.com |
2024-05-23 21:01:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Reports First Quarter 2024 Financial Results |
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 |
globenewswire.com |
2024-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT) |
NEW YORK , April 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cogent Biosciences, Inc. (NASDAQ: COGT) on behalf of the company's shareholders. The investigation seeks to determine whether Cogent Biosciences, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2024-04-18 13:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor |
WALTHAM, Mass. and BOULDER, Colo. |
globenewswire.com |
2024-04-09 13:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results |
• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected by YE 2025 |
globenewswire.com |
2024-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis |
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: |
globenewswire.com |
2024-02-22 16:30:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Oversubscribed $225 Million Private Placement |
Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials |
globenewswire.com |
2024-02-14 09:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting |
Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET |
globenewswire.com |
2024-02-05 11:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics |
WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2024 milestones ahead of its presentation at J.P. Morgan's 42nd annual healthcare conference. |
globenewswire.com |
2024-01-09 10:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference |
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 4:30 p.m. PT/7:30 p.m. ET. |
globenewswire.com |
2024-01-02 10:00:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment |
Cogent Biosciences Inc. shares COGT, -1.48% fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine potential competitors, in analysts' view. In a trial of bezuclastinib in patients with nonadvanced systemic mastocytosis, a rare blood disorder in which too many mast cells build up in the body, everyone treated with the therapy achieved at least 50% improvement in all relevant biomarker measures, Cogent said Friday at the American Society of Hematology annual meeting in San Diego. |
marketwatch.com |
2023-12-11 10:23:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) |
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose |
globenewswire.com |
2023-12-11 09:55:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) |
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 |
globenewswire.com |
2023-12-09 15:30:00 |
Czytaj oryginał (ang.) |
| Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium |
Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently approved therapies |
globenewswire.com |
2023-12-07 11:00:00 |
Czytaj oryginał (ang.) |